No connection

Search Results

GELS vs IMRN

GELS
Gelteq Limited
BEARISH
Price
$0.77
Market Cap
$8.2M
Sector
Healthcare
AI Confidence
95%
IMRN
Immuron Limited
BEARISH
Price
$0.79
Market Cap
$8.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GELS
--
IMRN
--
Forward P/E
GELS
--
IMRN
-79.3
P/B Ratio
GELS
0.7
IMRN
0.7
P/S Ratio
GELS
19.92
IMRN
1.08
EV/EBITDA
GELS
-3.15
IMRN
-52.59

Profitability

Gross Margin
GELS
72.07%
IMRN
63.69%
Operating Margin
GELS
-2969.43%
IMRN
-47.16%
Profit Margin
GELS
0.0%
IMRN
-62.14%
ROE
GELS
-42.99%
IMRN
-39.68%
ROA
GELS
-15.0%
IMRN
-21.93%

Growth

Revenue Growth
GELS
59.4%
IMRN
4.8%
Earnings Growth
GELS
--
IMRN
--

Financial Health

Debt/Equity
GELS
0.27
IMRN
0.02
Current Ratio
GELS
0.27
IMRN
8.04
Quick Ratio
GELS
0.14
IMRN
6.75

Dividends

Dividend Yield
GELS
--
IMRN
--
Payout Ratio
GELS
0.0%
IMRN
0.0%

AI Verdict

GELS BEARISH

GELS exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis. While the company shows strong top-line revenue growth (59.40%) and healthy gross margins (72.07%), these are completely offset by a catastrophic operating margin of -2969.43%. With a current ratio of 0.27 and a quick ratio of 0.14, the company lacks the liquidity to meet its short-term obligations. Despite trading below book value (P/B 0.70), the fundamental instability and long-term price decay make this a high-risk speculative asset.

Strengths
Strong Gross Margin of 72.07%
Robust YoY Revenue Growth of 59.40%
Low Debt-to-Equity ratio (0.27)
Risks
Severe liquidity shortage (Current Ratio 0.27)
Extreme operational inefficiency (Operating Margin -2969.43%)
Weak Piotroski F-Score (3/9) indicating deteriorating fundamentals
IMRN BEARISH

The deterministic health profile is weak, headlined by a Piotroski F-Score of 3/9, indicating significant financial deterioration. While the company maintains a strong liquidity position with a Current Ratio of 8.04 and negligible debt (D/E 0.02), these are offset by severe operational losses and a profit margin of -62.14%. The stock is in a clear long-term downtrend, losing over 85% of its value over five years, and the lack of recent earnings data suggests a lack of transparency or momentum. Despite trading below book value (P/B 0.70), the fundamental decay outweighs the valuation discount.

Strengths
Very low leverage with a Debt/Equity ratio of 0.02
Strong short-term liquidity (Current Ratio 8.04)
Trading at a discount to book value (P/B 0.70)
Risks
Weak financial health as evidenced by a Piotroski F-Score of 3/9
Severe negative profitability (Profit Margin -62.14%)
Extreme negative price momentum (1Y Change -51.9%)

Compare Another Pair

GELS vs IMRN: Head-to-Head Comparison

This page compares Gelteq Limited (GELS) and Immuron Limited (IMRN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile